Cubist is ditching 177 Optimer jobs after its $535M buyout

Just over a month after crossing the T's on a $535 million acquisition by Cubist Pharmaceuticals ($CBST), Optimer Pharmaceuticals is shedding 177 jobs in the U.S. and Canada, New Jersey's Star-Ledger reports. Massachusetts-based Cubist is shutting down Optimer's Garden State headquarters next year, according to the newspaper, and the company is working with affected employees to see if they might fit in elsewhere in its operations. Report

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.